UNH
UnitedHealth Group Incorporated
UNH has the edge over XGN overall, supported by lower modeled downside and stronger valuation.
XGN
Exagen Inc.
XGN's outlook is improving, though it still trails on the overall score.
UNH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Healthy |
UNH's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
XGN Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Weak | |
| Unavailable |
XGN's revenue is currently healthy, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
UNH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $405 | — |
| Cheap | 19x | $325 | -20% |
| Fair | 23x | $410 | +1.2% |
| Current | 23x | $405 | — |
| Expensive | 30x | $526 | +30% |
Historical ranges are pointers, not guarantees.
UNH's PE is in its fair range at 23x. If earnings grow as analysts expect, today's price would be 18x next year's earnings, in its cheap range.
XGN PE Valuation
XGN has no meaningful PE right now: it lost money over the past year.
UNH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Moderate | |
| Low |
Analysts expect UNH's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
XGN Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Growth | |
| Strongly improving | |
| Limited | |
| Low |
XGN has the edge over UNH on the outlook, with more favorable revenue expectations.
UNH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $22.65 | +29% |
| Q3 2026 | $17.55 | -8.5% |
| Q2 2026 | $15.58 | -33% |
| Q1 2026 | $13.28 | -44% |
| Q4 2025 | $13.23 | -15% |
| Q3 2025 | $19.17 | +25% |
| Q2 2025 | $23.09 | +53% |
| Q1 2025 | $23.89 | +46% |
| Q4 2024 | $15.51 | -35% |
UNH has the edge over XGN on earnings quality, reporting a profit while its opponent remains loss making.
XGN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.76 | +$0.16 |
| Q2 2026 | -$0.82 | +$0.07 |
| Q1 2026 | -$0.90 | -$0.06 |
| Q4 2025 | -$0.93 | -$0.10 |
| Q3 2025 | -$0.92 | +$0.02 |
| Q2 2025 | -$0.89 | +$0.08 |
| Q1 2025 | -$0.84 | +$0.25 |
| Q4 2024 | -$0.83 | +$0.51 |
XGN is still losing money, but far less than before: $0.76 per share over the past year, against $2.77 at its worst in late 2022.
UNH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $112.7B | -0.4% |
| Q2 2026 | $112B | +0.4% |
| Q1 2026 | $111.7B | +2% |
| Q4 2025 | $113.2B | +12% |
| Q3 2025 | $113.2B | +12% |
| Q2 2025 | $111.6B | +13% |
| Q1 2025 | $109.6B | +9.8% |
| Q4 2024 | $100.8B | +6.8% |
UNH's revenue has held roughly level: $113B last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.8% | +2 points |
| Q2 2026 | 7.1% | +2.5 points |
| Q1 2026 | 8.1% | -0.3 points |
| Q4 2025 | 0.3% | -7.4 points |
| Q3 2025 | 3.8% | -4.8 points |
| Q2 2025 | 4.6% | -3.4 points |
| Q1 2025 | 8.3% | +0.4 points |
| Q4 2024 | 7.7% | -0.4 points |
UNH has the edge over XGN on profitability, with a higher operating margin.
XGN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $18.4M | +6.8% |
| Q2 2026 | $19.9M | +16% |
| Q1 2026 | $17.3M | +12% |
| Q4 2025 | $16.6M | +22% |
| Q3 2025 | $17.2M | +38% |
| Q2 2025 | $17.2M | +14% |
| Q1 2025 | $15.5M | +7.5% |
| Q4 2024 | $13.7M | -0.8% |
XGN has the edge over UNH on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -24% | -5.9 points |
| Q2 2026 | -8.6% | +6.6 points |
| Q1 2026 | -20% | +2 points |
| Q4 2025 | -30% | -5.1 points |
| Q3 2025 | -18% | +19 points |
| Q2 2025 | -15% | +1.9 points |
| Q1 2025 | -22% | -0.9 points |
| Q4 2024 | -25% | +13 points |
XGN's operating margin was −24% last quarter, down 5.9 points from the same quarter a year ago.
UNH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.3B | -16% |
| Q2 2026 | $10.3B | +63% |
| Q1 2026 | $8.1B | +79% |
| Q4 2025 | $160M | -89% |
| Q3 2025 | $5.1B | -61% |
| Q2 2025 | $6.3B | +6.9% |
| Q1 2025 | $4.6B | +1037% |
| Q4 2024 | $1.5B | +$7.6B |
UNH has the edge over XGN on cash generation, producing positive trailing cash flow while its opponent burns cash.
XGN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$2.8M | -204% |
| Q2 2026 | $3.4M | +$6.5M |
| Q1 2026 | -$10.6M | +$139K |
| Q4 2025 | -$3.1M | -1509% |
| Q3 2025 | $2.7M | +$5M |
| Q2 2025 | -$3.1M | -$532K |
| Q1 2025 | -$10.8M | -$1.7M |
| Q4 2024 | $217K | -97% |
XGN has burned cash in almost every quarter: −$13M over the past year, against −$11M the year before.
UNH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -4M shares |
| 1 year | -0.7% | -6M shares |
| 3 years | -3.6% | -34M shares |
| 5 years | -5.5% | -53M shares |
| Available history | -6.6% | -64M shares |
UNH has the edge over XGN on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $3.4B |
| Q2 2026 | $1.6B |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $2.5B |
| Q1 2025 | $3B |
| Q4 2024 | $5B |
UNH spent $5B buying back its own shares over the past year, down 52% from the year before.
XGN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +2.8% | +685K shares |
| 1 year | +8.3% | +1.9M shares |
| 3 years | +40% | +7.2M shares |
| 5 years | +47% | +7.9M shares |
| Available history | +97% | +12.3M shares |
XGN has 25M diluted shares, up 8.3% from a year ago.
UNH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.7x | Healthy |
| Q2 2026 | 1.7x | Healthy |
| Q1 2026 | 2.2x | Moderate |
| Q4 2025 | 2.3x | Moderate |
| Q3 2025 | 1.7x | Healthy |
| Q2 2025 | 1.5x | Healthy |
| Q1 2025 | 1.3x | Healthy |
| Q4 2024 | 1.4x | Healthy |
UNH's net debt is about 1.7 years of its operating earnings (EBITDA), about the same as a year ago.
XGN Net Leverage
XGN's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
UNH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.4 | Neutral |
| Stochastic | 60.0 | Neutral |
UNH's weekly RSI is 56 (neutral) and its Stochastic is 60 (neutral).
XGN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 40.3 | Neutral |
| Stochastic | 38.4 | Neutral |
XGN's weekly RSI is 40 (neutral) and its Stochastic is 38 (neutral).
UNH PE vs Healthcare Sector
| Metric | UNH | Sector median | Relative |
|---|---|---|---|
| PE | 23x | 26x | 11% below |
| PE % | 47 | 29 | 18 pts above |
UNH is trading at 23x earnings, a 11% discount to the Healthcare sector's median of 26x.
XGN PE vs Healthcare Sector
XGN has no meaningful PE right now: it lost money over the past year.
UNH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $394.2 | 2.8% above |
| 20 week MA | $400.5 | 1.2% above |
| 50 week MA | $361.2 | 12% above |
| 100 week MA | $376.0 | 7.8% above |
| 200 week MA | $446.6 | 9.3% below |
UNH has the edge over XGN on trend strength, trading above more of its moving averages.
XGN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $7.39 | 40% below |
| 20 week MA | $6.68 | 34% below |
| 50 week MA | $5.21 | 15% below |
| 100 week MA | $6.05 | 27% below |
| 200 week MA | $4.23 | 4.3% above |
XGN has fallen below most of its moving averages, though it's still 4.3% above its 200-week average.
UNH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $296.0 | $340.8 | +15% |
| 2021 | $340.8 | $495.4 | +45% |
| 2022 | $495.4 | $531.3 | +7.3% |
| 2023 | $531.3 | $526.5 | -0.9% |
| 2024 | $526.5 | $510.0 | -3.1% |
| 2025 | $510.0 | $331.8 | -35% |
| 2026 YTD | $331.8 | $405.1 | +22% |
UNH has the edge over XGN on returns for 2026, with the stronger performance.
XGN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $25.7 | $12.3 | -52% |
| 2021 | $12.3 | $11.0 | -10% |
| 2022 | $11.0 | $2.45 | -78% |
| 2023 | $2.45 | $1.99 | -19% |
| 2024 | $1.99 | $4.71 | +137% |
| 2025 | $4.71 | $6.13 | +30% |
| 2026 YTD | $6.13 | $4.41 | -28% |
XGN's yearly returns have swung widely, from +137% in 2024 to −78% in 2022. It's down 28% so far in 2026.